Asahi Life Asset Management CO. LTD. bought a new position in Boston Scientific Corporation (NYSE: BSX) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,155 shares of the medical equipment provider's stock, valued at approximately $433,000. A

Aurora Investment Counsel bought a new position in Boston Scientific Corporation (NYSE: BSX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 43,857 shares of the medical equipment provider's stock, valued at approximately $1,872,000. A number of other institutional investors have also recently

Boston Scientific has corrected sharply due to EP and WATCHMAN slowdowns, but 74% of its portfolio continues healthy growth. Weakness in BSX's EP business appears addressable with new product launches like FARAWAVE Ultra and ICE, expected to drive recovery from 2H 2027 onward. Valuation is compelling: BSX trades at 15.27x forward earnings, a significant discount to peers and historical averages, despite resilient core businesses.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

B. Riley Wealth Advisors Inc. reduced its stake in Boston Scientific Corporation (NYSE: BSX) by 56.1% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 8,467 shares of the medical equipment provider's stock after selling 10,822 shares during the quarter. B. Riley Wealth

E. Ohman J or Asset Management AB cut its holdings in Boston Scientific Corporation (NYSE: BSX) by 91.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,275 shares of the medical equipment provider's stock after selling 541,890 shares during the

Boston Scientific has been heavily sold off, now trading at attractive valuations versus peers after multiple guidance cuts. Despite U.S. growth headwinds for WATCHMAN and electrophysiology, BSX delivered strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. International markets are driving robust growth for BSX, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S.

The 2,100 shares were acquired for ~$100,000 on August 5, 2026. This transaction represents a 14% increase in total direct equity holdings.

Michael F. Mahoney deployed ~$10.0 million on August 3, 2026, to acquire ~200,000 shares at a weighted average price of $48.34. The acquisition increased the CEO's total equity holdings by 13%, primarily expanding his direct position in the company.

MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026.